Hong Kong stocks opened lower in the morning session.$恒生指數(800000.HK)$opened 109 points or 0.7% lower at 16,628.$國企指數(800100.HK)$opened 40 points or 0.7% lower at 5,807.$恒生科技指數(800700.HK)$opened 40 points or 1.1% lower at 3,554. $藥明康德(02359.HK)$, whose net profit rose 21% in 2023, delayed two placing-funded investment projects by 2 years to the end of 2025, and its share price lost 2.8% to $41.55, while its sa...
The EPS decline likely left investors hesitant, as Sino Biopharmaceutical's performance, with a 34% loss including dividends, underperformed the broader market's 16% loss. This may signal unresolved challenges, given it's worse than the 6% annualised loss over the last half decade.
Sino Biopharmaceutical Limited's high P/S ratio may not be justified due to its slower revenue growth. Investors may hope for a business turnaround, but analysts lack confidence. The weak revenue outlook could risk the share price and shareholder investments.
Company's declining EPS, below market expectations, may have deterred investors. Past performance led to total loss for shareholders, raising future concerns. Dividend payouts, assumed reinvested, helped offset some losses.
中國生物製藥(ADR)股票討論區
HSI Opens 109 pts Lower as WUXI Series Slip
$藥明康德(02359.HK)$ , whose net profit rose 21% in 2023, delayed two placing-funded investment projects by 2 years to the end of 2025, and its share price lost 2.8% to $41.55, while its sa...
暫無評論